Loading...
Loading...
HRTX| Name | Value |
|---|---|
| Revenues | 29.6M |
| Cost of Revenue | 16.9M |
| Gross Profit | 12.8M |
| Operating Expense | 45.8M |
| Operating I/L | -33.1M |
| Other Income/Expense | 0.3M |
| Interest Income | 0.0M |
| Pretax | -32.8M |
| Income Tax Expense | -0.3M |
| Net Income/Loss | -32.5M |
Heron Therapeutics, Inc. is a biotechnology company specializing in developing treatments using its proprietary Biochronomer drug delivery technology. The company's product candidates, including SUSTOL and CINVANTI, address nausea and vomiting associated with chemotherapy, while ZYNRELEF and HTX-019 focus on postoperative pain management. Heron Therapeutics, Inc. generates revenue by commercializing these extended-release injections and intravenous formulations, providing healthcare solutions for patients undergoing cancer treatment and surgery.
